Nutex Health, Inc. (NUTX) Key Metrics
NUTX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $1.27B
- Enterprise value
- $852.1M
- P/E (TTM)
- 7.4 10-yr median 15.7
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.5 10-yr median 3.2
- Price / book
- 3.5 10-yr median 10.1
- EV / EBITDA
- 90.0 10-yr median 6.3
- Dividend yield
- —
- Beta
- 2.00
NUTX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNUTX valuation Price multiples at each fiscal year-end price.
NUTX returns How much profit the business earns on the capital it uses.
NUTX per-share figures Results divided by the shares outstanding at year-end.
NUTX financial health Debt, liquidity and how easily interest is covered.
NUTX efficiency & capital use Working capital cycle and where the cash goes.
NUTX valuation history
NUTX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NUTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NUTX cash returned to shareholders
NUTX price vs earnings per share
NUTX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.11B | $161.6M | $119.0M | $1.21B | $2.44B | $869.0M | $1.24B | $2.69B | $15.69B | $10.85B |
| Enterprise value | $1.28B | $458.3M | $372.8M | $1.44B | $2.58B | $993.7M | $1.35B | $2.70B | $15.69B | $10.85B |
| P/E ratio | 15.7 | 3.1 | — | — | 18.4 | 8.2 | 59.4 | — | — | — |
| Price / sales | 1.3 | 0.3 | 0.5 | 5.5 | 7.4 | 3.2 | 12.8 | — | — | — |
| Price / book | 3.4 | 1.1 | 1.9 | 12.6 | 21.3 | 10.1 | 43.9 | — | — | — |
| Price / free cash flow | 4.5 | 7.8 | — | 33.5 | 17.9 | 43.3 | — | — | — | — |
| Price / operating cash flow | 4.5 | 7.0 | 94.7 | 23.8 | 14.1 | 10.7 | 102.4 | — | — | — |
| EV / sales | 1.5 | 1.0 | 1.5 | 6.6 | 7.8 | 3.6 | 13.9 | — | — | — |
| EV / EBITDA | 4.4 | 3.1 | — | — | 14.1 | 6.3 | 35.5 | — | — | — |
| EV / free cash flow | 5.2 | 22.0 | — | 40.0 | 18.9 | 49.5 | — | — | — | — |
| Earnings yield | 6.4% | 32.3% | −38.5% | −35.2% | 5.4% | 12.2% | 1.7% | −0.1% | 0.0% | −0.1% |
| Free cash flow yield | 22.1% | 12.9% | −6.9% | 3.0% | 5.6% | 2.3% | −1.6% | −0.0% | −0.0% | −0.0% |
| Dividend yield | 6.7% | 4.0% | 4.4% | 4.2% | 5.9% | 6.8% | 1.5% | — | — | — |
| Shareholder yield (dividends + buybacks) | 7.1% | 4.0% | 4.4% | 4.2% | 5.9% | 6.8% | 1.9% | — | — | — |
| Share price at fiscal year-end | $164.62 | $31.69 | $27.00 | $285.00 | $618.00 | $202.50 | $300.00 | $375.00 | $3,750.00 | $5,250.00 |
| Per share | ||||||||||
| Revenue per share | $129.55 | $94.11 | $56.18 | $51.81 | $83.89 | $63.85 | $23.45 | $0.01 | $0.01 | $0.00 |
| Earnings per share | $10.48 | $10.23 | −$10.39 | −$100.36 | $33.55 | $24.69 | $5.05 | −$0.39 | $0.14 | −$3.60 |
| Operating cash flow per share | $36.73 | $4.54 | $0.29 | $11.96 | $43.89 | $18.94 | $2.93 | −$0.07 | −$0.17 | −$0.13 |
| Free cash flow per share | $36.35 | $4.09 | −$1.87 | $8.50 | $34.54 | $4.68 | −$4.87 | −$0.07 | −$0.17 | −$0.13 |
| Cash per share | $27.47 | $8.55 | $4.99 | $8.09 | $9.14 | $5.95 | $1.93 | $0.02 | $0.00 | $0.01 |
| Book value per share | $48.76 | $28.69 | $13.94 | $22.65 | $29.01 | $19.99 | $6.84 | −$0.21 | $0.57 | −$2.84 |
| Tangible book value per share | $43.56 | $22.92 | $5.42 | $13.62 | $28.55 | $19.73 | $5.63 | −$0.57 | −$0.21 | −$2.84 |
| Dividends per share | $10.99 | $1.26 | $1.18 | $12.10 | $36.52 | $13.76 | $4.57 | — | — | — |
| Capex per share | $0.37 | $0.45 | $2.15 | $3.46 | $9.34 | $14.26 | $7.80 | $0.00 | $0.00 | $0.00 |
| Debt per share | $52.01 | $66.72 | $62.55 | $63.13 | $45.18 | $34.98 | $28.97 | $0.19 | $0.09 | $0.02 |
| Shares outstanding | 6.8M | 5.1M | 4.4M | 4.2M | 4.0M | 4.3M | 4.1M | 7.2M | 4.2M | 2.1M |
| Change in shares outstanding | +32.5% | +15.7% | +4.2% | +7.1% | −7.9% | +3.7% | −42.4% | +71.7% | +102.5% | 0.0% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 29.8% | 50.2% | −58.2% | −403.6% | 132.3% | 185.7% | 156.1% | — | — | — |
| Return on invested capital (ROIC) | 43.3% | 29.9% | −7.8% | −109.6% | 72.4% | 87.3% | 25.5% | — | — | — |
| Return on assets (ROA) | 9.0% | 9.9% | −11.0% | −102.8% | 37.7% | 43.4% | 23.3% | −149.0% | 30.3% | −182.4% |
| Return on tangible assets | 8.0% | 8.3% | −12.7% | −107.9% | 33.8% | 34.5% | 12.0% | — | 956.2% | — |
| Free cash flow margin | 28.1% | 4.3% | −3.3% | 16.4% | 41.2% | 7.3% | −20.8% | −525.4% | — | — |
| Income quality (OCF / net income) | 3.51 | 0.44 | — | — | 1.31 | 0.77 | 0.58 | — | −1.23 | — |
| Financial health | ||||||||||
| Total debt | $351.4M | $340.3M | $275.8M | $267.2M | $178.6M | $150.1M | $119.9M | $1.4M | $386,189 | $50,000 |
| Cash & short-term investments | $185.6M | $43.6M | $22.0M | $34.3M | $36.1M | $25.5M | $8.0M | $119,267 | $9,449 | $10,522 |
| Net debt | $165.8M | $296.7M | $253.8M | $232.9M | $142.4M | $124.6M | $111.9M | $1.3M | $376,740 | $39,478 |
| Debt / equity | 1.07 | 2.33 | 4.49 | 2.79 | 1.56 | 1.75 | 4.24 | — | 0.16 | — |
| Debt / assets | 0.38 | 0.52 | 0.69 | 0.62 | 0.45 | 0.49 | 0.67 | 3.07 | 0.12 | 0.10 |
| Net debt / EBITDA | 0.58 | 2.00 | — | — | 0.78 | 0.79 | 2.94 | — | — | — |
| Current ratio | 3.41 | 2.08 | 1.56 | 1.79 | 4.09 | 4.31 | 0.63 | 0.29 | 0.06 | 0.08 |
| Quick ratio | 3.39 | 2.06 | 1.50 | 1.72 | 4.01 | 4.25 | 0.62 | 0.27 | 0.06 | 0.08 |
| Interest coverage | 12.4 | 6.6 | -1.9 | -32.6 | 27.5 | 23.8 | 9.8 | -2.9 | -15.5 | -173.9 |
| Working capital | $380.9M | $151.6M | $32.5M | $43.1M | $116.3M | $104.1M | −$26.4M | −$738,643 | −$904,700 | −$5.9M |
| Invested capital | $495.3M | $443.1M | $315.2M | $328.8M | $257.1M | $210.4M | $140.2M | −$236,845 | $2.7M | −$5.8M |
| Tangible asset value | $388.3M | $172.4M | $41.5M | $82.1M | $189.8M | $146.2M | $45.8M | −$4.1M | −$898,910 | −$5.9M |
| Net current asset value | $43.7M | −$160.9M | −$228.3M | −$213.5M | −$49.1M | −$25.7M | −$82.6M | −$1.6M | −$904,700 | −$5.9M |
| Graham number | $107.22 | $81.27 | — | — | $147.99 | $105.40 | $27.89 | — | $1.33 | — |
| Graham net-net per share | −$9.48 | −$45.37 | −$56.34 | −$54.73 | −$20.11 | −$12.51 | −$22.42 | −$0.23 | −$0.23 | −$3.08 |
| Capital allocation | ||||||||||
| Dividends paid | $74.3M | $6.4M | $5.2M | $51.2M | $144.3M | $59.1M | $18.9M | — | — | — |
| Share buybacks (net) | $5.0M | $0 | $0 | $0 | — | $120,000 | $4.1M | — | — | — |
| Dividend payout ratio | 104.9% | 12.3% | — | — | 108.9% | 55.7% | 90.3% | — | — | — |
| Dividends + buybacks / free cash flow | 32.3% | 30.9% | — | 142.4% | 105.7% | 294.8% | — | — | — | — |
| Capex / revenue | 0.3% | 0.5% | 3.8% | 6.7% | 11.1% | 22.3% | 33.3% | 0.0% | 0.0% | — |
| Capex / operating cash flow | 1.0% | 10.0% | 755.8% | 28.9% | 21.3% | 75.3% | 266.2% | — | — | — |
| Capex / depreciation | 0.12 | 0.12 | 0.54 | 1.11 | 4.82 | 10.27 | 13.03 | 0.00 | 0.00 | 0.01 |
| Stock-based compensation / revenue | 13.4% | 3.5% | 1.1% | 0.1% | 3.1% | 0.9% | 0.5% | 227.7% | 1,723.0% | — |
| R&D / revenue | — | — | — | — | 0.1% | 0.2% | 0.8% | 596.7% | 47.8% | — |
| SG&A / revenue | 19.3% | 12.2% | 14.6% | 9.1% | 1.7% | 1.6% | 61.7% | 1,273.6% | 3,380.7% | — |
| Efficiency | ||||||||||
| Days sales outstanding | 117.1 | 113.6 | 89.2 | 144.0 | 122.7 | 96.1 | 68.3 | 384.3 | 72.3 | — |
| Days of inventory on hand | 2.4 | 4.0 | 5.9 | 5.7 | 5.4 | 4.1 | 4.2 | 158.6 | — | — |
| Days payables outstanding | 26.6 | 25.2 | 42.2 | 37.2 | 31.5 | 16.3 | 10.5 | 2,681.5 | 227.8 | 202,554.2 |
| Cash conversion cycle (days) | 92.8 | 92.4 | 53.0 | 112.5 | 96.6 | 83.9 | 62.0 | -2,138.6 | -155.5 | — |
| Receivables turnover | 3.12 | 3.21 | 4.09 | 2.53 | 2.97 | 3.80 | 5.34 | 0.95 | 5.05 | 0.00 |
| Payables turnover | 13.70 | 14.46 | 8.65 | 9.81 | 11.59 | 22.42 | 34.63 | 0.14 | 1.60 | 0.00 |
| Inventory turnover | 150.80 | 90.92 | 61.49 | 64.24 | 67.07 | 88.68 | 86.66 | 2.30 | — | — |
| Asset turnover | 1.11 | 0.91 | 0.60 | 0.53 | 0.94 | 1.12 | 1.08 | 0.05 | 0.03 | 0.00 |
| Average receivables | $280.7M | $149.4M | $60.5M | $86.5M | $111.4M | $72.1M | $18.2M | $96,202 | $10,627 | $15,000 |
| Average payables | $31.5M | $19.6M | $24.6M | $20.8M | $13.1M | $5.2M | $1.2M | $457,680 | $352,180 | $262,488 |
| Average inventory | $2.9M | $3.1M | $3.5M | $3.2M | $2.3M | $1.3M | $463,494 | $27,073 | — | — |
| Intangibles / total assets | 3.8% | 4.5% | 9.4% | 8.8% | 0.5% | 0.4% | 2.8% | 572.3% | 98.2% | 0.0% |
Computed from NUTX's annual financial statements (latest annual report filed March 5, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NUTX valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Nutex Health traded at 15.7 times earnings, against a 10-year median of 15.7. Based on the latest twelve months, the trailing P/E is 7.4. Nutex Health earned a return on equity of 29.8% and a return on invested capital of 43.3% in fiscal 2025. It ended the year with $351.4 million of debt and $185.6 million in cash and short-term investments, net debt of $165.8 million. It returned $79.3 million to shareholders: $74.3 million in dividends and $5.0 million in share buybacks, 32% of free cash flow. The share count rose 227.0% from 2.1M to 6.8M over 9 years.
See the NUTX income statement, the NUTX chart for price history, or the NUTX stock overview for the latest quote and news.
NUTX key metrics FAQ
What is Nutex Health's P/E ratio?
Nutex Health's trailing P/E ratio is 7.4 based on the last twelve months of earnings (as of October 17, 2026). At the end of fiscal 2025 it was 15.7, compared with a 10-year median of 15.7.
What is Nutex Health's EV/EBITDA?
Nutex Health's enterprise value was 4.4 times EBITDA at the end of fiscal 2025 (enterprise value $1.3 billion, EBITDA $287.5 million); the current EV/EBITDA is 90.0.
What is Nutex Health's return on equity?
Nutex Health's return on equity (ROE) was 29.8% in fiscal 2025: net income of $70.8 million on average shareholders' equity of $237.9 million.
What is Nutex Health's ROIC?
Nutex Health's return on invested capital was 43.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Nutex Health have?
Nutex Health had total debt of $351.4 million at the end of fiscal 2025, a debt-to-equity ratio of 1.07 and $165.8 million of net debt (0.58 times EBITDA).
What is Nutex Health's dividend yield?
Nutex Health paid $74.3 million in dividends in fiscal 2025 ($10.99 per share), a payout ratio of 104.9%.
Does Nutex Health buy back its shares?
Yes. Nutex Health spent $5.0 million on net share repurchases in fiscal 2025 Shares outstanding changed +32.5% over the year, to 6.8M..
What is Nutex Health's free cash flow yield?
Nutex Health generated $245.6 million of free cash flow in fiscal 2025, a free cash flow yield of 22.1% on its market value at year-end ($1.1 billion).
What is Nutex Health's current ratio?
Nutex Health's current ratio was 3.41 at the end of fiscal 2025: current assets were 3.41 times current liabilities.